Teen Prodigy Develops AI to Enhance Chemotherapy Precision
In the bustling corridors of a New Jersey high school, 18-year-old Mythreya Dharani is quietly orchestrating a revolution in cancer treatment. While his peers navigate the typical teenage challenges, Mythreya has set his sights on a more formidable foe: cancer. He has developed an artificial intelligence model that predicts how well the chemotherapy drug cisplatin will work against specific tumours.
This innovation has earned him a finalist position in the 2026 Regeneron Science Talent Search, a testament to his ingenuity and scientific acumen. The implications of this development are profound. By forecasting a tumour's response to chemotherapy, doctors could tailor treatments to the individual, potentially increasing efficacy and minimising side effects.
Mythreya's journey began with a simple question: could AI bridge the gap between standardised cancer treatments and personalised medicine? His project, which falls under computational biology and bioinformatics, leverages machine learning algorithms to analyse tumour characteristics and predict treatment outcomes.
The Promise of Personalised Medicine
Personalised medicine has long been the holy grail of cancer treatment. While chemotherapy has been a staple in oncology, its one-size-fits-all approach often leads to variable outcomes. Mythreya's model could change this narrative, offering a glimpse into a future where treatments are tailored to the genetic and molecular profile of each patient's cancer.
By focusing on cisplatin, a commonly used chemotherapy drug, Mythreya's model could provide insights not only for this treatment but also pave the way for similar approaches with other drugs. This could lead to a paradigm shift in how oncologists approach chemotherapy, moving away from a generic protocol to more nuanced, patient-specific strategies.
Recognition and the Road Ahead
As one of the 40 finalists in the Regeneron Science Talent Search, Mythreya joins the ranks of young scientists tackling some of the most complex challenges of our time. Although he did not make it to the top 10, his work has not gone unnoticed. Alongside other New Jersey students like Edward Kang and Claire Jiang, who also achieved top honours, Mythreya represents the next wave of innovators poised to make significant contributions to medicine and technology.
Looking forward, the potential applications of Mythreya's work are manifold. With further research and development, his AI model could be integrated into clinical settings, offering oncologists a powerful tool in the fight against cancer. For now, Mythreya remains focused on refining his model, driven by the hope that one day his work will save lives.
